Optimal management of resected gastric cancer

References

• International Agency for Research on CancerGLOBOCAN 2012: Cancer fact sheet Available from: http://www.iacr.com.fr/index.php?option=com_content&view=article&id=101&Itemid=578Accessed May 10, 2018
   Google Scholar
• LiuDLuMLiJThe patterns and timing of recurrence after curative resection for gastric cancer in ChinaWorld J Surg Oncol201614130527931221
   PubMedGoogle Scholar
• LiangYDingXWangXPrognostic value of surgical margin status in gastric cancer patientsANZ J Surg201585967868424438078
   PubMed Web of Science ®Google Scholar
• AurelloPMagistriPNigriGSurgical management of microscopic positive resection margin after gastrectomy for gastric cancer: a systematic review of gastric R1 managementAnticancer Res201434116283628825368226
   PubMed Web of Science ®Google Scholar
• ZuHWangFMaYXueYStage-stratified analysis of prognostic significance of tumor size in patients with gastric cancerPLoS One201381e5450223382906
   PubMed Web of Science ®Google Scholar
• PacelliFPapaVCaprinoPSgadariABossolaMDogliettoGBProximal compared with distal gastric cancer: multivariate analysis of prognostic factorsAm Surg200167769770311450793
   PubMed Web of Science ®Google Scholar
• ZuHWangHLiCXueYClinicopathologic characteristics and prognostic value of various histological types in advanced gastric cancerInt J Clin Exp Pathol2014795692570025337210
   PubMed Web of Science ®Google Scholar
• SeoJYJinEHJoHJClinicopathologic and molecular features associated with patient age in gastric cancerWorld J Gastroenterol201521226905691326078567
   PubMed Web of Science ®Google Scholar
• KangW-MMengQ-BYuJ-CMaZ-QLiZ-TFactors associated with early recurrence after curative surgery for gastric cancerWorld J Gastroenterol201521195934594026019458
   PubMed Web of Science ®Google Scholar
• ZuHWangHLiCKangYXueYClinico-pathological features and prognostic analysis of gastric cancer patients in different age groupsHepatogastroenterology20156213722523025911900
   PubMedGoogle Scholar
• MigitaKTakayamaTSaekiKThe prognostic nutritional index predicts long-term outcomes of gastric cancer patients independent of tumor stageAnn Surg Oncol20132082647265423463091
   PubMed Web of Science ®Google Scholar
• JiangNDengJYDingXWPrognostic nutritional index predicts postoperative complications and long-term outcomes of gastric cancerWorld J Gastroenterol20142030105371054425132773
   PubMed Web of Science ®Google Scholar
• NozoeTNinomiyaMMaedaTMatsukumaANakashimaHEzakiTPrognostic nutritional index: a tool to predict the biological aggressiveness of gastric carcinomaSurg Today201040544044320425547
   PubMed Web of Science ®Google Scholar
• De FrancoLMarrelliDVoglinoCPrognostic value of perineural invasion in resected gastric cancer patients according to Lauren histotypePathol Oncol Res201824239340028555306
   PubMed Web of Science ®Google Scholar
• AurelloPBerardiGTiernoSMInfluence of perineural invasion in predicting overall survival and disease-free survival in patients with locally advanced gastric cancerAm J Surg2017213474875327613269
   PubMed Web of Science ®Google Scholar
• MitaKItoHFukumotoMSurgical outcomes and survival after extended multiorgan resection for T4 gastric cancerAm J Surg2012203110711121474116
   PubMed Web of Science ®Google Scholar
• ChengC-TTsaiC-YHsuJ-TAggressive surgical approach for patients with T4 gastric carcinoma: promise or myth?Ann Surg Oncol20111861606161421222167
   PubMed Web of Science ®Google Scholar
• DengJLiangHDiscussion of the applicability of positive lymph node ratio as a proper N-staging for predication the prognosis of gastric cancer after curative surgery plus extended lymphadenectomyAnn Surg20122566e35e3623154399
   PubMed Web of Science ®Google Scholar
• De ManzoniGVerlatoGBencivengaMImpact of super-extended lymphadenectomy on relapse in advanced gastric cancerEur J Surg Oncol201541453454025707350
   PubMed Web of Science ®Google Scholar
• DegiuliMSasakoMPontiARandomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancerBr J Surg20141012233124375296
   PubMed Web of Science ®Google Scholar
• GaliziaGLietoEDe VitaFModified versus standard D2 lymphadenectomy in total gastrectomy for nonjunctional gastric carcinoma with lymph node metastasisSurgery2015157228529625532433
   PubMed Web of Science ®Google Scholar
• ShirongCJianhuiCChuangqiCSurvival of proper hepatic artery lymph node metastasis in patients with gastric cancer: implications for D2 lymphadenectomyPLoS One2015103e011895325768441
   PubMed Web of Science ®Google Scholar
• ZhangJNiuZZhouYCaoSA comparison between the seventh and sixth editions of the American Joint Committee on Cancer/International Union against classification of gastric cancerAnn Surg20132571818623059507
   PubMed Web of Science ®Google Scholar
• HsuJ-TLinC-JSungC-MPrognostic significance of the number of examined lymph nodes in node-negative gastric adenocarcinomaEur J Surg Oncol201339111287129323973513
   PubMed Web of Science ®Google Scholar
• LiuY-YFangW-LWangFDoes a higher cutoff value of lymph node retrieval substantially improve survival in patients with advanced gastric cancer? Time to embrace a new digitOncologist20172219710627789777
   PubMed Web of Science ®Google Scholar
• KimYParkSHKimK-MThe influence of metastatic lymph node ratio on the treatment outcomes in the adjuvant chemoradiotherapy in stomach tumors (ARTIST) trial: a phase III trialJ Gastric Cancer201616210511027433396
   PubMed Web of Science ®Google Scholar
• JeuckTLAWittekindCGastric carcinoma: stage migration by immunohistochemically detected lymph node micrometastasesGastric Cancer201518110010824550066
   PubMed Web of Science ®Google Scholar
• JiexianJXiaoqinXLiliDClinical assessment and prognostic evaluation of tumor markers in patients with gastric cancerInt J Biol Markers201328219220023787496
   PubMed Web of Science ®Google Scholar
• XiaoJHeXWangZSerum carbohydrate antigen 19-9 and prognosis of patients with gastric cancerTumour Biol20143521331133424234331
   PubMedGoogle Scholar
• JingJ-XWangYXuX-QTumor markers for diagnosis, monitoring of recurrence and prognosis in patients with upper gastrointestinal tract cancerAsian Pac J Cancer Prev20141523102671027225556459
   PubMedGoogle Scholar
• ShimadaHNoieTOhashiMObaKTakahashiYClinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer AssociationGastric Cancer2014171263323572188
   PubMed Web of Science ®Google Scholar
• GiampieriRMaccaroniEMandolesiAMismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapyGastric Cancer201720115616326796888
   PubMed Web of Science ®Google Scholar
• HuZ-DHuangY-LQinB-DPrognostic value of neutrophil to lymphocyte ratio for gastric cancerAnn Transl Med2015345025861605
   PubMedGoogle Scholar
• ShimadaHTakiguchiNKainumaOHigh preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancerGastric Cancer201013317017620820986
   PubMed Web of Science ®Google Scholar
• GraziosiLMarinoEDe AngelisVRebonatoACavazzoniEDoniniAPrognostic value of preoperative neutrophils to lymphocytes ratio in patients resected for gastric cancerAm J Surg2015209233333725190544
   PubMed Web of Science ®Google Scholar
• DengQHeBLiuXPrognostic value of pre-operative inflammatory response biomarkers in gastric cancer patients and the construction of a predictive modelJ Transl Med20151316625885254
   PubMedGoogle Scholar
• OtsuHOkiEIkawa-YoshidaACorrelation of HER2 expression with clinicopathological characteristics and prognosis in resectable gastric cancerAnticancer Res20153542441244625862912
   PubMed Web of Science ®Google Scholar
• TerashimaMKitadaKOchiaiAImpact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancerClin Cancer Res201218215992600022977193
   PubMed Web of Science ®Google Scholar
• LiangJZhangJZhangTZhengZClinicopathological and prognostic significance of HER2 overexpression in gastric cancer: a meta-analysis of the literatureTumor Biol201435548494858
   PubMedGoogle Scholar
• ChenCYangJHuTPrognostic role of human epidermal growth factor receptor in gastric cancer: a systematic review and meta-analysisArch Med Res201344538038923871709
   PubMed Web of Science ®Google Scholar
• GuJZhengLWangYZhuMWangQLiXPrognostic significance of HER2 expression based on trastuzumab for gastric cancer (ToGA) criteria in gastric cancer: an updated meta-analysisTumor Biol201435653155321
   PubMedGoogle Scholar
• KimuraYOkiEYoshidaASignificance of accurate human epidermal growth factor receptor-2 (HER2) evaluation as a new biomarker in gastric cancerAnticancer Res20143484207421225075048
   PubMed Web of Science ®Google Scholar
• KurokawaYMatsuuraNKimuraYMulticenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancerGastric Cancer201518469169725224659
   PubMed Web of Science ®Google Scholar
• OhHSEomDWKangGHPrognostic implications of EGFR and HER-2 alteration assessed by immunohistochemistry and silver in situ hybridization in gastric cancer patients following curative resectionGastric Cancer201417340241123955257
   PubMed Web of Science ®Google Scholar
• FisherSBFisherKESquiresMHHER2 in resected gastric cancer: is there prognostic value?J Surg Oncol20141092616624122802
   PubMed Web of Science ®Google Scholar
• HsuJ-TChenT-CTsengJ-HImpact of HER-2 overexpression/amplification on the prognosis of gastric cancer patients undergoing resection: a single-center study of 1,036 patientsOncologist201116121706171322143936
   PubMed Web of Science ®Google Scholar
• SakuramotoSSasakoMYamaguchiTAdjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidineN Engl J Med2007357181810182017978289
   PubMed Web of Science ®Google Scholar
• PernotSVoronTPerkinsGLagorce-PagesCBergerATaiebJSignet-ring cell carcinoma of the stomach: impact on prognosis and specific therapeutic challengeWorld J Gastroenterol201521401142826523107
   PubMed Web of Science ®Google Scholar
• CorsoGMarrelliDPascaleVVindigniCRovielloFFrequency of CDH1 germline mutations in gastric carcinoma coming from high- and low-risk areas: metanalysis and systematic review of the literatureBMC Cancer2012121822225527
   PubMedGoogle Scholar
• XingXTangYBYuanGThe prognostic value of E-cadherin in gastric cancer: a meta-analysisInt J Cancer2013132112589259623169395
   PubMed Web of Science ®Google Scholar
• CorsoGCarvalhoJMarrelliDSomatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancerJ Clin Oncol201331786887523341533
   PubMed Web of Science ®Google Scholar
• Di BartolomeoMPietrantonioFPellegrinelliAOsteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancerGastric Cancer201619241242025862567
   PubMed Web of Science ®Google Scholar
• SaadAAAwedNMAbd ElkerimNNPrognostic significance of E-cadherin expression and peripheral blood micrometastasis in gastric carcinoma patientsAnn Surg Oncol201017113059306720563657
   PubMed Web of Science ®Google Scholar
• PengLZhanPZhouYPrognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysisMol Biol Rep201239109473948422729879
   PubMed Web of Science ®Google Scholar
• ChenJLiTWuYPrognostic significance of vascular endothelial growth factor expression in gastric carcinoma: a meta-analysisJ Cancer Res Clin Oncol2011137121799181221918901
   PubMed Web of Science ®Google Scholar
• LeeSJKimJGSohnSKNo association of vascular endothelial growth factor-A (VEGF-A) and VEGF-C expression with survival in patients with gastric cancerCancer Res Treat200941421820057967
   PubMed Web of Science ®Google Scholar
• LiuLMaX-LXiaoZ-LLiMChengS-HWeiY-QPrognostic value of vascular endothelial growth factor expression in resected gastric cancerAsian Pac J Cancer Prev20121373089309722994715
   PubMedGoogle Scholar
• LeiteMCorsoGSousaSMSI phenotype and MMR alterations in familial and sporadic gastric cancerInt J Cancer201112871606161320533283
   PubMed Web of Science ®Google Scholar
• AnJYKimHCheongJ-HHyungWJKimHNohSHMicrosatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5-FU based chemotherapy after R0 resectionInt J Cancer2012131250551121898388
   PubMed Web of Science ®Google Scholar
• FangW-LChangS-CLanY-TMicrosatellite instability is associated with a better prognosis for gastric cancer patients after curative surgeryWorld J Surg20123692131213822669398
   PubMed Web of Science ®Google Scholar
• KimSYChoiYYAnJYThe benefit of microsatellite instability is attenuated by chemotherapy in stage II and stage III gastric cancer: results from a large cohort with subgroup analysesInt J Cancer2015137481982525614197
   PubMed Web of Science ®Google Scholar
• DattaJMcMillanMTShangEKOmission of adjuvant therapy after gastric cancer resection: development of a validated risk modelJ Natl Compr Canc Netw201513553154125964639
   PubMed Web of Science ®Google Scholar
• KawazoeHShimasakiMUenoMRisk factors for discontinuation of s-1 adjuvant chemotherapy for gastric cancerJ Cancer20156546446925874010
   PubMed Web of Science ®Google Scholar
• QuJLiXQuX-JOptimal duration of fluorouracil-based adjuvant chemotherapy for patients with resectable gastric cancerPLoS One2013812e8319624386161
   PubMed Web of Science ®Google Scholar
• JoJ-CBaekJHKohS-JAdjuvant chemotherapy for elderly patients (aged 70 or older) with gastric cancer after a gastrectomy with D2 dissection: a single center experience in KoreaAsia Pac J Clin Oncol201511428228725856172
   PubMed Web of Science ®Google Scholar
• JinYQiuMWangDAdjuvant chemotherapy for elderly patients with gastric cancer after D2 gastrectomyPLoS One201381e5314923359796
   PubMed Web of Science ®Google Scholar
• ParkHSJungMKimHSProper timing of adjuvant chemotherapy affects survival in patients with stage 2 and 3 gastric cancerAnn Surg Oncol201522122423125081339
   PubMed Web of Science ®Google Scholar
• BangY-JKimY-WYangH-KAdjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trialLancet2012379981331532122226517
   PubMed Web of Science ®Google Scholar
• NohSHParkSRYangH-KAdjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trialLancet Oncol201415121389139625439693
   PubMed Web of Science ®Google Scholar
• SasakoMSakuramotoSKataiHFive-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancerJ Clin Oncol201129334387439322010012
   PubMed Web of Science ®Google Scholar
• YangLYangYQinQEvaluation of the optimal dosage of S-1 in adjuvant SOX chemotherapy for gastric cancerOncol Lett2015931451145725663930
   PubMed Web of Science ®Google Scholar
• TsuburayaAYoshidaKKobayashiMSequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trialLancet Oncol201415888689324954805
   PubMed Web of Science ®Google Scholar
• BajettaEFlorianiIDi BartolomeoMRandomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancerAnn Oncol20142571373137824728035
   PubMed Web of Science ®Google Scholar
• TatebeSTsujitaniSNakamuraSFeasibility study of alternate-day S-1 as adjuvant chemotherapy for gastric cancer: a randomized controlled trialGastric Cancer201417350851323948997
   PubMed Web of Science ®Google Scholar
• CunninghamDAllumWHStenningSPPerioperative chemotherapy versus surgery alone for resectable gastroesophageal cancerN Engl J Med20063551112016822992
   PubMed Web of Science ®Google Scholar
• YchouMBoigeVPignonJ-PPerioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trialJ Clin Oncol201129131715172121444866
   PubMed Web of Science ®Google Scholar
• Al-BatranS-EHomannNSchmalenbergHPerioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): a multicenter, randomized phase 3 trialJ Clin Oncol20173515_suppl4004
   Google Scholar
• RobbWBMessagerMGronnierCHigh-grade toxicity to neoadjuvant treatment for upper gastrointestinal carcinomas: what is the impact on perioperative and oncologic outcomes?Ann Surg Oncol201522113632363925676845
   PubMed Web of Science ®Google Scholar
• MirzaAPritchardSWelchIThe postoperative component of MAGIC chemotherapy is associated with improved prognosis following surgical resection in gastric and gastrooesophageal junction adenocarcinomasInt J Surg Oncol2013201378174224163764
   PubMedGoogle Scholar
• DaviesARGossageJAZylstraJTumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junctionJ Clin Oncol201432272983299025071104
   PubMed Web of Science ®Google Scholar
• MacdonaldJSSmalleySRBenedettiJChemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junctionN Engl J Med20013451072573011547741
   PubMed Web of Science ®Google Scholar
• SmalleySRBenedettiJKHallerDGUpdated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resectionJ Clin Oncol201230192327233322585691
   PubMed Web of Science ®Google Scholar
• KimSLimDHLeeJAn observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomachInt J Radiat Oncol Biol Phys20056351279128516099596
   PubMed Web of Science ®Google Scholar
• LeeJLimDHKimSPhase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trialJ Clin Oncol201230326827322184384
   PubMed Web of Science ®Google Scholar
• ParkSHSohnTSLeeJPhase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analysesJ Clin Oncol201533283130313625559811
   PubMed Web of Science ®Google Scholar
• KimTHParkSRRyuKWPhase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III-IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissectionInt J Radiat Oncol Biol Phys2012845e585e59222975616
   PubMed Web of Science ®Google Scholar
• ZhuWXuaDPuJA randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resectionRadiother Oncol2012104336136622985776
   PubMed Web of Science ®Google Scholar
• ZhouM-LKangMLiG-CGuoX-MZhangZPostoperative chemoradiotherapy versus chemotherapy for R0 resected gastric cancer with D2 lymph node dissection: an up-to-date meta-analysisWorld J Surg Oncol201614120927502921
   PubMed Web of Science ®Google Scholar
• Al-BatranSEHomannNSchmalenbergHPerioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trialJ Clin Oncol201735suppl 154004
   Google Scholar
• StahlMWalzMKStuschkeMPhase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junctionJ Clin Oncol200927685185619139439
   PubMed Web of Science ®Google Scholar
• van HagenPHulshofMCCMvan LanschotJJBPreoperative chemoradiotherapy for esophageal or junctional cancerN Engl J Med2012366222074208422646630
   PubMed Web of Science ®Google Scholar
• ValentiniVCelliniFMinskyBDSurvival after radiotherapy in gastric cancer: systematic review and meta-analysisRadiother Oncol200992217618319586672
   PubMed Web of Science ®Google Scholar
• LeongTSmithersBMMichaelMTOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG)BMC Cancer201515153226194186
   PubMedGoogle Scholar